Zhixiang Jintai announced that the telicibimab injection independently developed by the company was included in the list of priority review varieties by the Drug Evaluation Center of the State Drug Administration. The proposed indication is chronic spontaneous urticaria. It is the first IL-4Rα antibody drug in China to apply for marketing as a new drug with this indication. Currently, 4 indications of this product, including seasonal allergic rhinitis and chronic spontaneous urticaria in adults, are in the new drug marketing application review stage, and multiple indications are in different clinical trials. The product still needs to go through review, on-site inspection and approval, and there is uncertainty about whether it will be successfully marketed and when.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.